Bolstering its nutrition ingredient portfolio, Lonza, Basel, Switzerland, has entered a global commercial partnership with Lipogen for the exclusive rights to sell phosphatidylserine (PS) and PS-based formulations in dietary supplements, medical foods and food and beverages under the Lonza name. Lonza intends to roll out launch activities in the U.S. in the fourth quarter of 2011, and expand to other global regions thereafter.

PS, which may reduce the risk of dementia and cognitive dysfunction in the elderly as well as reduce stress and mental fatigue, is the only cognitive health ingredient in the U.S. to receive a qualified health claim from FDA. Lipogen PS also obtained FDA affirmed Generally Recognized As Safe (GRAS) status.